Iqvia Hldgs Stock Price, News & Analysis
Company Description
IQVIA Holdings Inc. (NYSE: IQV) is described as a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. The company’s stock trades on the New York Stock Exchange under the ticker symbol IQV, as indicated in its SEC filings.
According to company disclosures and recent press releases, IQVIA’s portfolio of solutions is powered by IQVIA Connected Intelligence™. These offerings are built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA states that it is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.
Business focus and core activities
Based on the provided information, IQVIA focuses on several major activity areas within life sciences and healthcare:
- Clinical research services – IQVIA provides services that support clinical development, including late-stage clinical trials and broader clinical research activities for pharmaceutical, biotech, medical device and diagnostic organizations. The company highlights its role in helping accelerate clinical development and bring treatments to market more efficiently.
- Commercial insights – IQVIA offers commercial insights to life sciences and healthcare clients. These insights are derived from health data, analytics and technology, and are used to support activities such as drug launches and broader commercial decision-making.
- Healthcare intelligence and analytics – IQVIA provides healthcare intelligence built on large-scale health information, advanced analytics and Healthcare-grade AI. The company emphasizes its capabilities in generating data-driven insights for a range of healthcare stakeholders.
In addition, IQVIA’s disclosures reference an R&D-focused business, including Research & Development Solutions, and a smaller contract sales and medical solutions business. The company also notes that it has supported site and participant payments across more than 200 geographies, reflecting the global reach of its clinical trial-related operations.
Technology, AI and data capabilities
IQVIA places strong emphasis on the use of artificial intelligence and advanced technology in its offerings. The company describes its capabilities as including Healthcare-grade AI®, agentic AI and advanced analytics, which are applied across areas such as clinical trial execution, medical affairs and healthcare analytics.
In a recent announcement, IQVIA disclosed a strategic collaboration with Amazon Web Services (AWS), naming AWS as its Preferred Agentic Cloud Provider to power a next-generation AI platform. Under this collaboration, IQVIA plans to deploy its AI platform on AWS to enhance scalable, secure and intelligent automation across clinical trial execution, medical affairs and healthcare analytics. The companies also intend to explore new opportunities in life science analytics to support data-driven insights and solutions.
IQVIA highlights that its AI-powered capabilities are built on approaches designed to address privacy, regulatory compliance and patient safety, and that it aims to deliver AI to standards of trust, scalability and precision that are demanded by the industry.
Global operations and workforce
Company materials state that IQVIA has tens of thousands of employees in over 100 countries. These employees include experts in healthcare, life sciences, data science, technology and operational excellence. This global footprint supports IQVIA’s work with clients and clinical trial sites around the world.
IQVIA also reports that it has been recognized for its relationships with clinical trial sites. For example, the company received the WCG Pinnacle Award for Site Relationships in Professionalism and Communication, based on feedback from participants in a global site relationship survey. IQVIA links this recognition to its focus on operational excellence and collaboration in clinical research.
Privacy, compliance and data protection
IQVIA describes itself as a global leader in protecting individual patient privacy. It states that it uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate them with treatment paths and therapies.
The company emphasizes that it is committed to using AI responsibly, with AI-powered capabilities built on approaches that address privacy and regulatory requirements. IQVIA’s disclosures highlight the importance of regulatory compliance and patient safety across its services.
Clients and stakeholders
According to the company’s own descriptions, IQVIA’s insights and execution capabilities support a broad range of healthcare stakeholders. These include biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other organizations in the healthcare ecosystem. IQVIA indicates that its work helps these stakeholders gain a deeper understanding of diseases, human behaviors and scientific advances, with the goal of advancing progress toward cures and improved outcomes.
Corporate background
Polygon data provided in the input notes that IQVIA is the result of a merger completed in 2016 between Quintiles, described as a global contract research organization, and IMS Health, described as a healthcare data and analytics provider. That description also references business segments focused on outsourced late-stage clinical trials, technology and analytics services for healthcare clients and a contract sales business. While specific segment labels may evolve over time, this background helps explain IQVIA’s combined focus on clinical research, data, analytics and commercial support for life sciences and healthcare organizations.
Recent developments and partnerships
Recent news items illustrate how IQVIA continues to develop its offerings and partnerships:
- Agentic AI platform on AWS – IQVIA announced a strategic collaboration with AWS to deploy its AI platform on AWS infrastructure, with the goal of improving clinical trial automation, accelerating trial processes and advancing life science analytics.
- Clinical Trial Financial Suite (CTFS) – IQVIA announced the launch of its Clinical Trial Financial Suite, an AI-enabled platform designed to orchestrate financial aspects of clinical trials, including budgeting, contracting, forecasting and payment workflows. The first module, CTFS Site Payments, focuses on automating site payment processes using agentic AI.
- Partnerships with Veeva Systems – IQVIA and Veeva Systems announced global clinical and commercial partnerships and the resolution of legal disputes. The partnerships are intended to allow customers to combine software, data, technology and service offerings from both companies in clinical and commercial contexts.
- Network expansion through NEXT Oncology – A separate press release notes that NEXT Oncology, described as an Avacare business, joined the IQVIA family in 2025 and aligned with the Avacare Clinical Research Network, IQVIA’s network of specialized clinical research sites. This is presented as expanding collaboration and capabilities within IQVIA’s patient- and site-centric approach.
Capital markets and regulatory filings
IQVIA’s SEC filings confirm that its common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on the New York Stock Exchange under the symbol IQV. The company files periodic and current reports with the SEC, including Forms 8-K that disclose material events such as financial results, credit agreement amendments and leadership changes.
For example, IQVIA filed an 8-K to report financial results for the third quarter ended September 30, 2025, and separate 8-K filings to describe a planned chief financial officer transition and an amendment to its credit agreement. These filings provide investors with information on the company’s financial condition, capital structure and governance developments.
Role in the healthcare and life sciences ecosystem
Across its disclosures and news releases, IQVIA positions itself as an organization that connects clinical research, data, analytics, technology and commercial support for life sciences and healthcare. By combining clinical research services with healthcare intelligence and commercial insights, and by applying Healthcare-grade AI and advanced analytics, the company aims to support the development, approval and commercialization of medical treatments and to contribute to improved patient outcomes and population health.
Stock Performance
Iqvia Hldgs (IQV) stock last traded at $173.26. Over the past 12 months, the stock has lost 0.6%, ranking #1,081 in 52-week price change. At a market capitalization of $29.1B, IQV is classified as a large-cap stock with approximately 167.9M shares outstanding.
Latest News
Iqvia Hldgs has 10 recent news articles. Of the recent coverage, 1 article coincided with positive price movement and 9 with negative movement. Key topics include AI, acquisition, partnership, clinical trial. View all IQV news →
SEC Filings
Iqvia Hldgs has filed 5 recent SEC filings, including 2 Form 4, 1 Form SCHEDULE 13G/A, 1 Form ARS, 1 Form DEF 14A. The most recent filing was submitted on March 27, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all IQV SEC filings →
Financial Highlights
Iqvia Hldgs generated $16.3B in revenue over the trailing twelve months, retaining a 33.3% gross margin, operating income reached $2.2B (13.4% operating margin), and net income was $1.4B, reflecting a 8.3% net profit margin. Diluted earnings per share stood at $7.84. The company generated $2.7B in operating cash flow. With a current ratio of 0.75, short-term liquidity bears monitoring.
Upcoming Events
IQVIA.ai capability expansion
Iqvia Hldgs has 1 upcoming scheduled event. The next event, "IQVIA.ai capability expansion", is scheduled for October 1, 2026 (in 179 days). Investors can track these dates to stay informed about potential catalysts that may affect the IQV stock price.
Short Interest History
Short interest in Iqvia Hldgs (IQV) currently stands at 4.2 million shares, up 11.0% from the previous reporting period, representing 2.5% of the float. Over the past 12 months, short interest has increased by 43.3%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Iqvia Hldgs (IQV) currently stands at 2.5 days, up 87.1% from the previous period. This days-to-cover ratio represents a balanced liquidity scenario for short positions. The days to cover has increased 128.7% over the past year, indicating either rising short interest or declining trading volume. The ratio has shown significant volatility over the period, ranging from 1.1 to 6.1 days.
IQV Company Profile & Sector Positioning
Iqvia Hldgs (IQV) operates in the Diagnostics & Research industry within the broader Services-commercial Physical & Biological Research sector and is listed on the NYSE. In monthly performance, the stock ranks #877 among all tracked companies.
Investors comparing IQV often look at related companies in the same sector, including Agilent Technologies Inc (A), Mettler-Toledo (MTD), Labcorp Holdings Inc (LH), IDEXX Laboratories (IDXX), and Natera Inc (NTRA). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate IQV's relative position within its industry.